FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound represented by the formula (I), or to a pharmaceutically acceptable salt thereof, exhibiting immunomodulatory activity against PD-L1 (programmed death-ligand 1). In the formula (I), R1 is selected from the group consisting of F, Cl, Br, and I; R2 and R3 each are independently selected from the group consisting of H and a C1-3 alkyl, optionally substituted with 1, 2, or 3 Ra; Ra constitutes CH3. Invention also relates to specific compounds presented below, a pharmaceutical composition containing the above compounds, and an application thereof in the production of a medicinal product associated with the PD-L1 immunomodulator.
EFFECT: creation of a compound with immunomodulatory activity against PD-L1.
9 cl, 4 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
| MACROCYCLIC COMPOUND WITH FUNCTIONS OF WEE1 INHIBITOR AND ITS APPLICATION OPTIONS | 2018 |
|
RU2783243C2 |
| THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
| DERIVATIVES OF QUINOLINE-PYRROLIDINE-2-ONE AND APPLICATION THEREOF | 2019 |
|
RU2771314C1 |
| SPIRO COMPOUNDS AS ERK INHIBITORS AND THEIR USE | 2020 |
|
RU2800042C1 |
| S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
| CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
| PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-RK INHIBITORS | 2020 |
|
RU2796163C1 |
